CN1872080B - Drop pills of thevetoside and preparation method - Google Patents
Drop pills of thevetoside and preparation method Download PDFInfo
- Publication number
- CN1872080B CN1872080B CN2005100136303A CN200510013630A CN1872080B CN 1872080 B CN1872080 B CN 1872080B CN 2005100136303 A CN2005100136303 A CN 2005100136303A CN 200510013630 A CN200510013630 A CN 200510013630A CN 1872080 B CN1872080 B CN 1872080B
- Authority
- CN
- China
- Prior art keywords
- thevetin
- drop
- thevetoside
- adjuvant
- starch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000006187 pill Substances 0.000 title claims abstract description 134
- 238000002360 preparation method Methods 0.000 title claims description 34
- 238000000034 method Methods 0.000 claims abstract description 16
- 239000002671 adjuvant Substances 0.000 claims description 64
- GZVMBXDQUQRICT-TZNWHQCUSA-N 3-[(3s,5r,8r,9s,10s,13r,14s)-14-hydroxy-3-[(2s,3r,4r,5r,6s)-3-hydroxy-4-methoxy-6-methyl-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyoxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6, Chemical compound C1([C@@]2(C)CC[C@H]3[C@H]([C@]2(CC1)O)CC[C@H]1[C@]3(C)CC[C@@H](C1)O[C@@H]1[C@H](O)[C@H]([C@@H]([C@H](C)O1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)OC)C1=CC(=O)OC1 GZVMBXDQUQRICT-TZNWHQCUSA-N 0.000 claims description 60
- 229930191001 Thevetin Natural products 0.000 claims description 60
- 239000003814 drug Substances 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 54
- 238000002156 mixing Methods 0.000 claims description 35
- 229920002472 Starch Polymers 0.000 claims description 28
- 239000008107 starch Substances 0.000 claims description 28
- 235000019698 starch Nutrition 0.000 claims description 28
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 24
- 239000008101 lactose Substances 0.000 claims description 24
- 238000009413 insulation Methods 0.000 claims description 23
- 238000010438 heat treatment Methods 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 22
- 238000002844 melting Methods 0.000 claims description 22
- 230000008018 melting Effects 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 22
- 239000002826 coolant Substances 0.000 claims description 21
- 229920002545 silicone oil Polymers 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 11
- 229940057995 liquid paraffin Drugs 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
- 239000008158 vegetable oil Substances 0.000 claims description 4
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims 4
- 229930182470 glycoside Natural products 0.000 claims 3
- 150000002338 glycosides Chemical class 0.000 claims 3
- 241000208327 Apocynaceae Species 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 229940097217 cardiac glycoside Drugs 0.000 claims 1
- 239000002368 cardiac glycoside Substances 0.000 claims 1
- 125000003563 glycoside group Chemical group 0.000 claims 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims 1
- 229930002534 steroid glycoside Natural products 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 32
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 32
- 239000000811 xylitol Substances 0.000 description 32
- 235000010447 xylitol Nutrition 0.000 description 32
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 32
- 229960002675 xylitol Drugs 0.000 description 32
- 239000000758 substrate Substances 0.000 description 27
- 229940079593 drug Drugs 0.000 description 16
- 238000009472 formulation Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 235000010489 acacia gum Nutrition 0.000 description 11
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- -1 hydroxypropyl Chemical group 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000006225 natural substrate Substances 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 230000035943 smell Effects 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000208011 Digitalis Species 0.000 description 1
- 241001411320 Eriogonum inflatum Species 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
A dripping pill of thevetoside and its preparing process are disclosed. It has high natural level and safety and low toxic by-effect.
Description
Technical field
The present invention relates to field of medicaments, particularly, relating to Chinese medicine is that raw material is made the medicine with cardiotonic.
Background technology
Thevetin is a Folium Digitalis Purpureae class cardiac tonic, and the thevetin odorless dissolves in ethanol, its disintegration of tablet time is long, and the supplementary product consumption ratio is big, and child, old people, bed patient and dysphagia patients are taken inconvenience, compliance is poor, has influenced the performance of thevetin therapeutical effect.List marketing at present tablet arranged.
Application number: 03157887.X, the applying date: 2003.9.15, applicant: Nanchang Hongyi Science Co., Ltd, denomination of invention: the patent documentation of drop pills of thevetoside and preparation method thereof provides drop pills of thevetoside and preparation method thereof, and this drop pill drug use Polyethylene Glycol and other adjuvants are made drop pill with thevetin; Though this drop pill overcomes the defective of present tablet, has accelerated dissolution rate, there is the not high defective of natural degree of the adjuvant that uses in this drop pill.
Expansion and human back to nature requirement along with the market global range, use the low medicine of toxic and side effects, especially pure natural medical more and more becomes people's first-selection, dropping pill formulation be a kind of have efficient, quick-acting new medicine preparations, it has overcome the shortcoming and deficiency of Chinese medicine preparation in the past, but present dropping pill formulation generally faces following problem: 1, drop pill adjuvant pure natural degree is not high: at present, drop pill substrate adjuvant mostly is synthetic, natural degree is lower, the searching of new alternative substrate adjuvant, the searching of the alternative substrate adjuvant that particularly natural degree is high and preparation technology thereof determine, it is again very difficult thing, because the required preparation condition of at present common possible natural substrates adjuvant succedaneum is very harsh, it all is to influence the key that drop pill prepares molding that adjuvant temperature and drop pill thereof drip the system condition.The too high then viscosity of adjuvant melt temperature is low, and poor plasticity is though the adjuvant melt temperature is crossed lowplastcity by force, but drop pill has shortcomings such as easily sticking ball, distortion, therefore, seek pure natural degree height, and the adjuvant that is suitable for substituting existing drop pill substrate is a very job of hardships.2, the drop pill outlet encounters problems: along with expanding economy, more and more internationalize in market, China is also just making great efforts to adapt to this trend, present Chinese medicine dripping pills preparation as health food, successful export to many countries, but also face many problems at present, because different countries is different to the approval of the selected adjuvant of Chinese medicine dropping pill formulation, especially industrial flourishing Europe, more strict to food adjuvant and medical auxiliary materials, and as the selected chemosynthesis adjuvant (as Polyethylene Glycol) of the dropping pill formulation of health food outlet not in the catalogue of some national food additive, it is very unfavorable that this moves towards the international market to the Chinese medicine dropping pill formulation, becomes the stumbling-block that Chinese medicine enters the international market, therefore, seek the new of one or more, can be particularly important, also very urgent for the substrate adjuvant that the international market is accepted.3, the shortcoming of mouthfeel and onset speed: the mouthfeel of Chinese medicine and preparation thereof is relatively poor to be the big characteristics of one, people when taking some drugs to the frightened of disagreeable taste that medicine had even be better than fear far away to disease, What is more, some patients are because can not overcome the poor taste of Chinese medicine or its preparation or abnormal smells from the patient and abandon the treatment of Chinese medicine, though can improve mouthfeel as medicine being made capsule or sugar coated tablet, reducing stimulates, but disintegration rate prolongs, be unfavorable for the rapid onset of medicine, to some disease, particularly need the disease of the rapid onset of medicine inapplicable.4, the preparation process difficulty of drop pill suitability for industrialized production: in the replacement process of dropping pill formulation adjuvant, determining of the preparation process of its suitability for industrialized production is very difficult something, as the ratio of the melt temperature of substrate adjuvant, the proportioning of dripping system temperature, adjuvant and medicine, dropper bore, condensing agent etc. all are the factors that influence drop pill, therefore, the replacement of substrate and to be suitable for suitability for industrialized production be a job consuming time, as to expend substantial contribution.
In order to change drop pill substrate adjuvant for a long time based on the situation of chemosynthesis adjuvant, it is low to solve the pure natural degree that present drop pill substrate faced, and can not satisfy more and more that people require back to nature, take low toxicity, the problem of the pure natural medical that has no side effect; Also can solve some problems that Chinese medicine preparation, particularly dropping pill formulation are run in exit procedure, strengthen the competitiveness of international market; The present invention has invented the pure Chinese medicine dripping pills preparation that a kind of toxic and side effects is low, evident in efficacy, moderate, adapt to industrialized great production by a large amount of tests and the research of preparation process.
Summary of the invention
The purpose of this invention is to provide a kind of drop pills of thevetoside with the preparation of new type natural substrate adjuvant.
Another object of the present invention provides a kind of preparation method of thevetin.
The selected substrate adjuvant of the present invention is resulting by a large amount of tests, it is little to have molecular weight, soluble in water, and molten diffusing speed is faster, pure natural degree height, toxic and side effects is low, and can reduce the medicine irritation abnormal smells from the patient, has the oral cavity of improvement acid-base value during the buccal of oral cavity, improve the characteristics of oral cavity smell, the used substrate adjuvant of the present invention is the agent of food sedan-chair flavor, takes that mouthfeel is good, the acceptant characteristics of patient, is the direction of following substrate adjuvant development.
The consumption of drug component of the present invention and the selection of adjuvant thereof also grope to sum up to draw through the inventor in a large number, medicine of the present invention is formed and is comprised: thevetin, appropriate amount of auxiliary materials, wherein adjuvant comprises filler and plasticity substrate, described filler adjuvant is selected from the natural adjuvant of following one or more plant origins: sorbitol, xylitol, lactose, maltose, and they contain the water of crystallization chemical compound; Described plasticity substrate is selected from following one or more the natural adjuvant of plant origin: pregelatinized Starch, carboxymethyl starch, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, arabic gum, alginic acid, dextrin, cyclodextrin, agar, lactose;
In the adjuvant of preferred drug component of the present invention, described filler adjuvant is selected from following one or more the natural adjuvant of plant origin: xylitol, lactose; Described plasticity substrate is selected from following one or more the natural adjuvant of plant origin: starch, arabic gum;
Best substrate adjuvant of the present invention is xylitol and starch, and xylitol is 1:0.2～1:0.3 with the ratio of the weight of starch; Or be lactose and starch, lactose is 1:0.2～1:0.3 with the ratio of the weight of starch; Or be xylitol and arabic gum, the ratio of the weight of xylitol and arabic gum is 1:0.2～1:0.4.
Adjuvant is 1:0.1～1:1 with the ratio of the weight of thevetin in the pharmaceutical composition of the present invention;
Adjuvant is 1:0.1～1:0.6 with the ratio of the weight of thevetin in the preferred pharmaceutical composition of the present invention;
Adjuvant is 1:0.2～1:0.4 with the ratio of the weight of thevetin in the best pharmaceutical composition of the present invention.
Medicine mesostroma adjuvant of the present invention and amount of drug are than being the scope that allows on the galenic pharmacy, and medicine described here can be that crude drug also can be the effective ingredient extract.
Medicine of the present invention can adopt the preparation of Chinese medicine preparation conventional method; make common any preparation at present; but, preferably adopt following method to be prepared into dropping pill formulation, but this can not limit protection scope of the present invention in order to make each crude drug of this medicine bring into play drug effect better.
The preparation method of medicine of the present invention is as follows:
(a) get thevetin, adjuvant is standby;
(b) in appropriate amount of auxiliary materials, add thevetin, fully mix, mixture is at 45～115 ℃ of heating and meltings, stir, mixing time is 1～120 minute, insulation, at 45～95 ℃ of temperature following system, dropper bore is 1.0～4.0 millimeters, splash in-20～25 ℃ liquid paraffin, methyl-silicone oil or the vegetable oil, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Further preferred manufacturing procedure is:
The mixture heated melt temperature is 60～85 ℃ in the step (b), and mixing time is 10～30 minutes, and dripping a system temperature and be 60～85 ℃, dropper bore is 1.1～3.5 millimeters, and condensing agent is 0～18 ℃ liquid paraffin or a methyl-silicone oil.
Best preparation method is:
The mixture heated melt temperature is 64 ℃ in the step (b), and dripping a system temperature and be 64 ℃, dropper bore is 1.2～2.5 millimeters, and condensing agent is 0 ℃ a methyl-silicone oil.
More than form when producing and to increase or to reduce according to corresponding ratio, as large-scale production can be unit with kilogram or with the ton, small-scale production can be unit with the gram also, and weight can increase or reduce, but the crude drug material weight proportion constant rate between each composition.
Medicine of the present invention can be determined usage and dosage according to patient's situation in use, but every day 1-3 times, and every day, each crude drug consumption was as the criterion with the state-promulgated pharmacopoeia dosage, was no more than the pharmacopeia ormal weight.
The drop pill that the present invention is prepared, conventional drop pill advantage is simple as preparing except having, steady quality, can make liquid medicine solidification, convenient drug administration, efficient, quick-acting, its biggest advantage is:
1, the selected adjuvant pure natural of the present invention degree height: the substrate adjuvant that employed substrate adjuvant derives from natural plants or originates based on natural plants among the present invention, for example: selected substrate adjuvant is xylitol and starch or lactose and starch or xylitol and arabic gum, this substrate adjuvant has pure natural degree height, toxic and side effects is low, mouthfeel is good, dissolve scattered time limit is short, rapid-action, it is a kind of new medium adjuvant, can be used for substituting present chemosynthesis substrate adjuvant, the drop pill made from this kind adjuvant, it is low to solve the pure natural degree that present drop pill substrate faced, and more and more can not satisfy people and require back to nature, take low toxicity, the problem of the pure natural medical that has no side effect.
2, some problems in the outlet of solution Chinese medicine: medicine of the present invention also can solve Chinese medicine preparation, some problems of in exit procedure, being run into of dropping pill formulation particularly, solve because different countries, especially the European countries of industry prosperity are to the difference identification of the selected adjuvant of Chinese medicine dropping pill formulation, overcome as the selected adjuvant Polyethylene Glycol of the dropping pill formulation of the health food outlet defective in some national food additive catalogue not, improve the Chinese medicine dripping pills preparation and move towards the international market, strengthen the competitiveness of international market.
3, solve the relatively poor problem of drop pill taste and further improve drug effect speed (dissolve scattered time limit): the medicinal dropping ball made from this kind substrate adjuvant of the present invention, can improve Chinese medicine preparation, the particularly present not good shortcoming of dropping pill formulation taste, improve mouthfeel, more easy for patients to accept, and the drop pill that adopts the selected adjuvant of medicine of the present invention to make has shorter dissolve scattered time limit.
4, higher safety and solve some problems in the drop pill storage process: the selected substrate of the present invention is not only additive, nutrient commonly used in the food industry, and can do medicinal, but do not see that it uses as the drug matrices adjuvant, therefore, with regard to substrate, be perfectly safe, have no side effect, a large amount of evidences, the drop pill that this adjuvant is made can reduce effective ingredient separating out in storage process, the sticking ball of drop pill, easy shortcomings such as moisture absorption deliquescing, but the big production of suitability for industrialized.
To those skilled in the art, technology contents disclosed according to the present invention, those skilled in the art will very clear other embodiment of the present invention, and the embodiment of the invention is only as example.Under the situation of not violating purport of the present invention and scope, can carry out various changes and improvements to the present invention.For example, use different crude drug or extract or active constituents of medicine or effective ingredient and adjuvant provided by the present invention to make various different preparations, particularly drop pill, but as long as use adjuvant of the present invention, all within protection domain of the present invention.
In order to understand the present invention better, the drop pills of thevetoside made from the new substrate of the present invention (according to embodiment 1 preparation, hereinafter to be referred as new drop pills of thevetoside) below; Test explanation advantages of the present invention such as the dissolve scattered time limit of the drop pill of making for the substrate adjuvant with the Polyethylene Glycol (according to application number be: the 03157887.X patent documentation specific embodiment 1 prepares, hereinafter to be referred as old drop pills of thevetoside), drop pill soft durometer, the sticking ball of drop pill.
Test example 1: dissolve scattered time limit, weight differential contrast experiment's example
In vitro tests
New drop pills of thevetoside and old drop pills of thevetoside compare, and by measuring dissolve scattered time limit, investigate its good releasing effect; By measuring indexs such as the ball method of double differences is different, whether ripe, whether be fit to suitability for industrialized production if investigating its preparation technology.
1. test medication: new drop pills of thevetoside, old drop pills of thevetoside.
2. method and result:
Dissolve scattered time limit: by " method is measured under this item of Chinese pharmacopoeia; The ball method of double differences is different: by " method is measured under this item of Chinese pharmacopoeia.Result of the test sees Table 1.
Three batches in table 1 with new drop pills of thevetoside and old drop pills of thevetoside dissolve scattered time limit, weight differential relatively
Above-mentioned experimental data shows, different being controlled in the pharmacopeia prescribed limit of the older drop pills of thevetoside of the dissolve scattered time limit ball method of double differences few, new, old drop pills of thevetoside of new drop pills of thevetoside.The result of the test explanation, the new drop pills of thevetoside that the new medium adjuvant is made is more conducive to medicine and plays a role in the shortest time, different all being controlled in the pharmacopeia prescribed limit of the ball method of double differences new, old drop pills of thevetoside, but suitability for industrialized production.
Test example 2: the comparative observation of new drop pills of thevetoside and old drop pills of thevetoside soft durometer, the sticking ball of drop pill
Compare by new drop pills of thevetoside and old drop pills of thevetoside, measure indexs such as above-mentioned, investigate its effect.
1. test medication: new drop pills of thevetoside; Old drop pills of thevetoside.
2. method and result:
Get each three batches of new drop pills of thevetoside and old drop pills of thevetoside, be loaded in the porcelain vase respectively, and use the bottle stopper good seal.Putting it into the bottom has in the exsiccator of saturated Nacl (humidity 75%) solution, exsiccator is put into 40 ℃ of drying baker of constant temperature again, and timing sampling is observed situations such as drop pill soft durometer, the sticking ball of drop pill, the results are shown in Table 2.1, table 2.2.
Three batches of old drop pills of thevetoside reserved sample observings of table 2.1 relatively
Table 2.2: three batches of new drop pills of thevetoside and old drop pills of thevetoside character observation are relatively
Table 2.1,2.2 test data show that new drop pills of thevetoside soft durometer changes similar to old drop pills of thevetoside, strong slightly; New drop pills of thevetoside glues the ball variation, firmness change is similar to old drop pills of thevetoside.The result of the test explanation, the sticking ball of new, old drop pills of thevetoside changes, firmness change is similar, and the alternative present chemosynthesis adjuvant of this natural substrates adjuvant is described, but suitability for industrialized production.
The specific embodiment
Embodiment 1
(a) get thevetin fine powder 5g, xylitol 25.3g, starch 6.7g is standby;
(b) get xylitol and starch mix homogeneously, adding above-mentioned thevetin fine powder mixes, mixture stirs at 64 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 2
(a) get thevetin 5.6g, lactose 26.7g, starch 9.1g is standby;
(b) get lactose and starch mix homogeneously, adding above-mentioned thevetin fully mixes, mixture stirs at 64 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 3
(a) get thevetin 4.0g, xylitol 25.5g, arabic gum 8.6g is standby;
(b) get xylitol and arabic gum mix homogeneously, adding above-mentioned thevetin fully mixes, mixture stirs at 64 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 4
(a) get thevetin fine powder 6.0g, xylitol 18.0g, starch 6.5g is standby;
(b) get xylitol and starch mix homogeneously, adding above-mentioned thevetin fine powder fully mixes, mixture stirs at 45～70 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 60～70 ℃ of temperature following system, dropper bore is 1.21～2.5 millimeters, splashes in-10～10 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 5
(a) get thevetin 25g, xylitol 62.5g, starch 37.5g is standby;
(b) get xylitol and starch mix homogeneously, add above-mentioned thevetin, mixture stirs at 45～115 ℃ of heating and meltings, and mixing time is 1～30 minute, insulation, at 45～95 ℃ of temperature following system, dropper bore is 1.0～4.0 millimeters, splashes in-20～25 ℃ the vegetable oil, makes 3000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 6
(a) get thevetin 15g, maltose 100g is standby;
(b) get maltose and add above-mentioned thevetin, mixture is at 55～75 ℃ of heating and meltings, stir, mixing time is 5～12 minutes, and insulation is 1.20～3.0 millimeters at 55～75 ℃ of temperature following system, dropper bore, splash in 0～15 ℃ the liquid paraffin, make 4000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly
Embodiment 7
(a) get thevetin fine powder 20g, xylitol 80g, cyclodextrin 20g is standby;
(b) get xylitol and cyclodextrin mixing mixing, add above-mentioned thevetin fine powder, mixture stirs at 45～115 ℃ of heating and meltings, mixing time is 5～20 minutes, and insulation is dripped system 58～70 ℃ of insulations, splash in 12 ℃ of liquid paraffin, make 5000 drop pill of drop pill, promptly.
Embodiment 8
(a) get thevetin 30g, xylitol 99g, pregelatinized Starch 15g is standby;
(b) get xylitol and pregelatinized Starch mix homogeneously, add above-mentioned thevetin, mixture stirs at 60～75 ℃ of heating and meltings, and mixing time is 10～60 minutes, insulation, at 55～65 ℃ of temperature following system, dropper bore is 1.0～3.5 millimeters, splashes in-20～25 ℃ the vegetable oil, makes 5000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 9
(a) get thevetin fine powder 3.5g, lactose 26.6g, starch 6.4g is standby;
(b) get mixing of lactose and starch, add above-mentioned thevetin fine powder, mixture stirs at 60～85 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 60～85 ℃ of temperature following system, dropper bore is 1.1～3.5 millimeters, splashes in 0～18 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 10
(a) get thevetin 40g, xylitol 62.5g, arabic gum 37.5g is standby;
(b) get the mixing mixing of xylitol and arabic gum, add above-mentioned thevetin, mixture stirs at 60～85 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 60～85 ℃ of temperature following system, dropper bore is 1.1～3.5 millimeters, splashes in 0～18 ℃ the liquid paraffin, makes 3000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 11
(a) get thevetin 45g, xylitol 80g, alginic acid 20g is standby;
(b) get xylitol and alginic acid mixing mixing, add above-mentioned thevetin, mixture stirs at 60～85 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 60～85 ℃ of temperature following system, dropper bore is 1.21～3.5 millimeters, splashes in 0～15 ℃ the methyl-silicone oil, makes 4000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 12
(a) get thevetin 50g, xylitol 166g, sodium carboxymethyl cellulose 34g is standby;
(b) get xylitol and sodium carboxymethyl cellulose mix homogeneously, add above-mentioned thevetin, mixture stirs at 60～85 ℃ of heating and meltings, and mixing time is 10～20 minutes, insulation, at 60～75 ℃ of temperature following system, dropper bore is 1.5～3.5 millimeters, splashes in 10～18 ℃ the liquid paraffin, makes 6000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 13
(a) get thevetin 55g, lactose 40g, agar 10g is standby;
(b) get lactose and agar mix homogeneously, add above-mentioned thevetin, mixture stirs at 60～70 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 62～67 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 4 ℃ the methyl-silicone oil, makes 3000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 14
(a) get thevetin 5.5g, xylitol 18.5g, arabic gum 6.5g is standby;
(b) get xylitol and arabic gum mix homogeneously, add above-mentioned thevetin, mixture stirs at 55～85 ℃ of heating and meltings, and mixing time is 5～30 minutes, insulation, at 58～68 ℃ of temperature following system, dropper bore is 1.21～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 15
(a) get thevetin 6.0g, lactose 17.0g, hydroxypropyl emthylcellulose 8.5g is standby;
(b) getting lactose and hydroxypropyl emthylcellulose mixes, add above-mentioned thevetin, fully mix, mixture is at 64 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, and insulation is 1.2～2.5 millimeters at 64 ℃ of temperature following system, dropper bore, splash in 0 ℃ the methyl-silicone oil, make 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 16
(a) get thevetin 7.0g, xylitol 26.5g, methylcellulose 4.0g is standby;
(b) get xylitol and methylcellulose mixing, adding above-mentioned thevetin fully mixes, mixture stirs at 60～70 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 62～66 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 17
(a) get thevetin 3.5g, sorbitol 15.0g, carboxymethyl starch 5.0g is standby;
(b) get sorbitol and carboxymethyl starch mixing, adding above-mentioned thevetin fully mixes, mixture stirs at 58～78 ℃ of heating and meltings, and mixing time is 20～50 minutes, insulation, at 58～68 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0～10 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 18
(a) get thevetin 5.5g, xylitol 25.5g, lactose 5g is standby;
(b) get xylitol and lactose mixing, adding above-mentioned thevetin fully mixes, mixture stirs at 60～70 ℃ of heating and meltings, and mixing time is 15～25 minutes, insulation, at 62～66 ℃ of temperature following system, dropper bore is 1.21～2.5 millimeters, splashes in 0～15 ℃ the liquid paraffin, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Claims (10)
1. drop pills of thevetoside, wherein thevetin is the cardiac glycoside mixture that obtains in the apocynaceae plant Semen Thevetiae kernel, wherein mainly is Semen Thevetiae time glycosides first C
30H
44O
9, Semen Thevetiae time glycosides second C
30H
46O
8With single acetyl Semen Thevetiae time glycosides second C
32H
48O
9Three kinds of cardiac glycosidees, it is characterized in that this medicine composition comprises: thevetin, appropriate amount of auxiliary materials, described adjuvant are lactose and starch, and lactose is 1: 0.2～1: 0.3 with the ratio of the weight of starch; Described adjuvant is 1: 0.1～1: 1 with the ratio of the weight of thevetin.
2. drop pills of thevetoside according to claim 1 is characterized in that the adjuvant and the ratio of the weight of thevetin are 1: 0.1～1: 0.6.
3. drop pills of thevetoside according to claim 1 is characterized in that the adjuvant and the ratio of the weight of thevetin are 1: 0.2～1: 0.4.
4. the described drop pills of thevetoside of claim 1 is characterized in that this medicine is to be grouped into by following one-tenth: thevetin 5.6g, lactose 26.7g, starch 9.1g.
5. the described drop pills of thevetoside of claim 1 is characterized in that this medicine is to be grouped into by following one-tenth: thevetin fine powder 3.5g, lactose 26.6g, starch 6.4g.
6. the preparation method of the arbitrary described drop pills of thevetoside of claim 1～3 is characterized in that this method comprises the steps:
(a) get thevetin, adjuvant is standby;
(b) in appropriate amount of auxiliary materials, add thevetin, fully mix, mixture is at 45～115 ℃ of heating and meltings, stir, mixing time is 1～120 minute, insulation, at 45～95 ℃ of temperature following system, dropper bore is 1.0～4.0 millimeters, splash in-20～25 ℃ liquid paraffin, methyl-silicone oil or the vegetable oil, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
7. the preparation method of drop pills of thevetoside as claimed in claim 6, it is characterized in that the mixture heated melt temperature is 60～85 ℃, mixing time is 10～30 minutes, dripping the system temperature and be 60～85 ℃, dropper bore is 1.1～3.5 millimeters, and condensing agent is 0～18 ℃ liquid paraffin or a methyl-silicone oil.
8. the preparation method of drop pills of thevetoside as claimed in claim 7 is characterized in that the mixture heated melt temperature is 64 ℃, and dripping a system temperature and be 64 ℃, dropper bore is 1.2～2.5 millimeters, and condensing agent is 0 ℃ a methyl-silicone oil.
9. the preparation method of drop pills of thevetoside according to claim 4 is characterized in that:
(a) get thevetin 5.6g, lactose 26.7g, starch 9.1g is standby;
(b) get lactose and starch mix homogeneously, adding above-mentioned thevetin fully mixes, mixture stirs at 64 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
10. the preparation method of drop pills of thevetoside according to claim 5 is characterized in that:
(a) get thevetin fine powder 3.5g, lactose 26.6g, starch 6.4g is standby;
(b) get mixing of lactose and starch, add above-mentioned thevetin fine powder, mixture stirs at 60～85 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 60～85 ℃ of temperature following system, dropper bore is 1.1～3.5 millimeters, splashes in 0～18 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100136303A CN1872080B (en) | 2005-06-01 | 2005-06-01 | Drop pills of thevetoside and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100136303A CN1872080B (en) | 2005-06-01 | 2005-06-01 | Drop pills of thevetoside and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1872080A CN1872080A (en) | 2006-12-06 |
| CN1872080B true CN1872080B (en) | 2011-05-18 |
Family
ID=37482790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005100136303A Expired - Fee Related CN1872080B (en) | 2005-06-01 | 2005-06-01 | Drop pills of thevetoside and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1872080B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1490015A (en) * | 2003-09-15 | 2004-04-21 | 南昌弘益科技有限公司 | Thevina drops and preparation thereof |
-
2005
- 2005-06-01 CN CN2005100136303A patent/CN1872080B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1490015A (en) * | 2003-09-15 | 2004-04-21 | 南昌弘益科技有限公司 | Thevina drops and preparation thereof |
Non-Patent Citations (1)
| Title |
|---|
| 王巍.新基质复方丹参滴丸的研究.第二军医大学学位论文.2004,1-26. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1872080A (en) | 2006-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1872075B (en) | Drop pills of hemsleyadin, and preparation method | |
| CN1872052B (en) | Drop pills of simvastatin, and preparation method | |
| CN1872137B (en) | Drop pills of total glycoside of Jiaogulan, and preparation method | |
| CN1872080B (en) | Drop pills of thevetoside and preparation method | |
| CN1872036B (en) | Drop pills of agrimophol, and preparation method | |
| CN1872053B (en) | Drop pills of daphnetin, and preparation method | |
| CN1872050B (en) | Drop pills of silymarin, and preparation method | |
| CN101194910A (en) | Dropping pills containing acegastrodine and method for preparing the same | |
| CN1872108B (en) | Drop pills of centella total glycoside, and preparation method | |
| CN101194907B (en) | Dropping pills containing noscapine and method for preparing the same | |
| CN1872054B (en) | Drop pills of coumarin acetic acid, and preparation method | |
| CN1872318B (en) | Drop pills of oil of zedoary turmeric, and preparation method | |
| CN1872112B (en) | Drop pills of total saponin of gen-seng haulms, and preparation method | |
| CN1872045B (en) | Drop pills of lysionotin, and preparation method | |
| CN1872062B (en) | Fibrauretine, and preparation method | |
| CN1872044B (en) | Medication for treating coronary heart disease | |
| CN1872030B (en) | Drop pills of anticancer drugs, and preparation method | |
| CN1872059B (en) | Drop pills of matrine, and preparation method | |
| CN1872037B (en) | Drop pills of paeonol, and preparation method | |
| CN101194904B (en) | Dropping pills containing perhexiline maleic acid and method for preparing the same | |
| CN1872064B (en) | Drop pills of piperazine ferulic acid, and preparation method | |
| CN1872076B (en) | Drop pills of cucurbitacine, and preparation method | |
| CN1872040B (en) | Drop pills of sodium ferulic acid, and preparation method | |
| CN100592910C (en) | Drop pills of lentinan, and preparation method | |
| CN101194903B (en) | Dropping pills containing Isocarboxazid and method for preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110518 Termination date: 20190601 |